News

November 26, 2020November 25, 2020

New $100M Program Aims to Improve Diversity in Clinical Trials

News, syndicated

A new $100-million program aims to improve the diversity of participants in U.S. clinical trials with the ultimate goal of achieving better health outcomes and parity in care for underserved ... Read more

November 24, 2020November 24, 2020

ALKS 4230-Keytruda Combo Found to Reduce Tumor Size, Halt Disease Progression

News

The combination of Keytruda (pembrolizumab) and ALKS 4230 was able to halt disease progression and reduce tumor size in a small group of heavily pre-treated patients with advanced ovarian ... Read more

November 19, 2020November 19, 2020

Study to Examine if Blood Test Can Detect Cancer Early in Low-Risk Women

News

The University of Texas’ MD Anderson Cancer Center, in collaboration with the National Cancer Institute and Golfers Against Cancer, is evaluating the usefulness of a blood test called CA-125 at detecting ovarian ... Read more

November 17, 2020November 17, 2020

ImmunoGen Teams Up With Huadong Medicine to Develop Mirvetuximab in China

News

ImmunoGen has announced a collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co, a subsidiary of Huadong Medicine, to develop and commercialize the ovarian cancer treatment mirvetuximab soravtansine to patients in ... Read more

November 12, 2020November 12, 2020

CA125 Blood Test Useful in Diagnosing Ovarian Cancer in Routine Setting

News

A blood test measuring levels of the protein cancer antigen 125 (CA125) can help detect ovarian cancer in a primary care setting with considerable accuracy, a study reported. The ... Read more

November 10, 2020November 10, 2020

Lynparza Combo Approved in EU as First-line Maintenance for Advanced Ovarian Cancer

News

The European Commission has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and ... Read more

November 5, 2020November 5, 2020

First Patient Dosed in Phase 2 Study of Cancer Vaccine Combination in Ovarian Cancer

News

The first patient has been dosed in a Phase 2 extension study investigating the cancer vaccine DSP-7888 (ombipepimut-S) in combination with the checkpoint inhibitor Keytruda (pembrolizumab), in people with ... Read more

November 3, 2020November 3, 2020

Zejula Approved in Europe as Maintenance Therapy for Advanced Ovarian Cancers

News

The European Commission has approved Zejula (niraparib) as a first-line maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer, who respond to platinum-based chemotherapy. This ... Read more

October 29, 2020October 29, 2020

3 Companies Join Forces to Test Personalized ‘Teaching’ Vaccine for Ovarian Cancer

News

TransGene, NEC, and BostonGene have entered a strategic collaboration to test TG4050, an investigational personalized vaccine that aims to treat ovarian and head and neck cancers, according to a press release. ... Read more

October 27, 2020October 27, 2020

Pilot Study Grants Available for Ovarian Cancer Research

News

Under its Pilot Study Awards program, the Rivkin Center is funding innovative research projects that seek to expand current knowledge about ovarian cancer, the non-profit has announced. Awarded grants ... Read more